Menu
Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1
Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization [Corrigendum]
Authors Smith, Giroud, Wiggins, Gower F, Thorley JA, Stolpe B, Mazzolin, Dyson, Rappoport J
Received 6 May 2015
Accepted for publication 6 May 2015
Published 16 June 2015 Volume 2015:10(1) Pages 3987—3988
Corrigendum
Smith PJ, Giroud M, Wiggins HL, et al. Int J Nanomedicine. 2012;7:2045–2055.
Page 2054, Figure 11, the text “Average no of NPs in lumen: Nf =2.1×10-3” should read “Average no of NPs in lumen:
Nf =2.1×10-2”.
Page 2054, Figure 11, the figure legend “Figure 11 A series of calculations to estimate the number of nanoparticles that could enter a vesicle under the incubation conditions described in materials and methods. It is estimated that nanoparticles are nearly 25,000 times more likely to enter cells when they are bound to the membrane than in the fluid phase.” should read “Figure 11 A series of calculations to estimate the number of nanoparticles that could enter a vesicle under the incubation conditions described in materials and methods. It is estimated that nanoparticles are nearly 2,500 times more likely to enter cells when they are bound to the membrane than in the fluid phase.”
Page 2054, first column, line 13, the sentence “Even though the latter might be an overestimation, the current analyses suggest that under these conditions nanoparticles are nearly 25,000 times more likely to enter cells bound to the inner membrane of a vesicle than through the fluid phase.” should read “Even though the latter might be an overestimation, the current analyses suggest that under these conditions nanoparticles are nearly 2,500 times more likely to enter cells bound to the inner membrane of a vesicle than through the fluid phase”.
Read the original article
© 2015 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.